Janeway Child Health Centre

The trials here

What the 35 trials at this site are about, from their registry records.

Conditions

• Childhood cancers35 trials
• Acute lymphoblastic leukaemia10 trials
• Neuroblastoma6 trials
• Sarcoma6 trials
• Kidney cancer5 trials
• Down syndrome3 trials
• Acute myeloid leukaemia1 trial
• Glioblastoma1 trial
• Lung cancer1 trial
• Myeloproliferative neoplasms1 trial
• Neuroendocrine tumours1 trial
• Ovarian cancer1 trial

Phase

• Phase 323 trials
• Phase 27 trials
• Phase 2/31 trial

Status

• Completed18 trials
• Active, not recruiting10 trials
• Recruiting7 trials

Lead sponsor

• Children's Oncology Group20 trials
• National Cancer Institute (NCI)14 trials
• University of Calgary1 trial

Running trials

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· National Cancer Institute (NCI)· Source

  Contact: Lisa A. Goodyear (principal investigator)

• Active, not recruiting

  Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  NCT04759586· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT04546399· Phase 2· National Cancer Institute (NCI)· Source

  Contact: Lisa A. Goodyear (principal investigator)

• Recruiting

  A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  NCT04322318· Phase 2· Children's Oncology Group· Source

  Contact: Lisa A. Goodyear (principal investigator)

• Recruiting

  Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  NCT03959085· Phase 3· Children's Oncology Group· Source

  Contact: Lisa A. Goodyear (principal investigator)

• Active, not recruiting

  Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349· Phase 2· Children's Oncology Group· Source

• Active, not recruiting

  A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  NCT03914625· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

  NCT03581292· Phase 2· Children's Oncology Group· Source

• Recruiting

  Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  NCT03126916· Phase 3· Children's Oncology Group· Source

  Contact: Lisa A. Goodyear (principal investigator)

• Active, not recruiting

  Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579· Phase 2· Children's Oncology Group· Source

• Recruiting

  Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181· Phase 3· Children's Oncology Group· Source

  Contact: Lisa A. Goodyear (principal investigator)

• Active, not recruiting

  Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Project: Every Child for Younger Patients With Cancer

  NCT02402244· Children's Oncology Group· Source

  Contact: Lisa A. Goodyear (principal investigator)

• Active, not recruiting

  Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

  NCT02101853· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

  NCT02306161· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

  NCT02112916· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  NCT02176967· Phase 3· Children's Oncology Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers7 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Kidney cancer2 recruiting
• Neuroblastoma2 recruiting
• Down syndrome1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  NCT03223753· Phase 3· Children's Oncology Group· Source

• Completed

  Re-Irradiation of Progressive or Recurrent DIPG

  NCT03126266· University of Calgary· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Children's Oncology Group· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Children's Oncology Group· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Children's Oncology Group· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Children's Oncology Group· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Children's Oncology Group· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Children's Oncology Group· Source

• Completed

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  NCT00085735· Phase 3· Children's Oncology Group· Source

• Completed

  Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

  NCT00026312· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241· Children's Oncology Group· Source